MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Cancer Research

Topics

Physics

Cancer Oncology

Medicine

Internal Medicine

Surgery

Show all topics

DOI

10.1158/1078-0432.ccr-17-0754